Creative Biolabs Advances Microbiome-Based Drug Development with Enhanced LBP Analytics
TL;DR
Creative Biolabs' advanced microbial service platform offers a competitive edge by streamlining microbiome-based drug development, reducing time and costs before clinical testing.
The platform employs strain identification, contaminant analysis, and stability evaluation, utilizing techniques like 16S rRNA sequencing and MALDI-TOF mass spectrometry for precise results.
By standardizing microbiome-based drug development, Creative Biolabs enhances therapeutic efficacy and safety, paving the way for healthier futures through advanced microbial research.
Creative Biolabs introduces a groundbreaking platform for microbiome-based drugs, featuring probiotic strain products engineered to express bioactive factors directly within hosts.
Found this article helpful?
Share it with your network and spread the knowledge!
Creative Biolabs has taken a significant step forward in the field of microbiome-based drug development with the launch of an advanced microbial service platform. This initiative is set to provide a more standardized and controllable technical pathway from strain screening to product finalization, addressing critical bottlenecks in the development of Live Biotherapeutic Products (LBPs).
The platform's comprehensive approach includes strain identification, contaminant analysis, formulation development, viability monitoring, and stability evaluation. By employing advanced techniques such as 16S rRNA sequencing, MALDI-TOF mass spectrometry, and whole genome sequencing, Creative Biolabs aims to enhance the efficiency and reliability of LBP development. This is particularly important given the challenges of strain characterization and the inherent vulnerability of live microbial formulations to contamination.
Moreover, the company's focus on formulation science and stability studies, including cryoprotectant screening and enteric coat evaluation, is expected to generate quality data crucial for IND or NDA submissions. The addition of a portfolio of probiotic reference materials further supports methodological validation and testing reproducibility, marking a significant advancement in the field.
This development is not just a technical achievement but a potential game-changer for the industry. By integrating biology and analytics more deeply, Creative Biolabs' platform could offer greater predictability and control in the development of LBPs, paving the way for more effective microbiome-based therapies. This is especially relevant as the scientific community continues to explore the therapeutic potential of the microbiome, with implications for treating a wide range of diseases.
Curated from 24-7 Press Release
